Edwards Lifesciences (EW) Given a $190.00 Price Target by Cowen Analysts

Cowen set a $190.00 price target on Edwards Lifesciences (NYSE:EW) in a research report report published on Friday. The brokerage currently has a buy rating on the medical research company’s stock.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Edwards Lifesciences from a buy rating to a hold rating in a research report on Thursday, October 25th. Barclays set a $143.00 price target on Edwards Lifesciences and gave the company a sell rating in a research report on Wednesday, October 24th. SunTrust Banks dropped their price target on Edwards Lifesciences to $170.00 and set a buy rating for the company in a research report on Friday, August 10th. ValuEngine cut Edwards Lifesciences from a buy rating to a hold rating in a research report on Wednesday, August 8th. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $150.00 to $157.00 and gave the company an overweight rating in a research report on Thursday, October 11th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $158.45.

Edwards Lifesciences stock opened at $162.01 on Friday. Edwards Lifesciences has a one year low of $110.68 and a one year high of $175.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. The firm has a market capitalization of $34.03 billion, a price-to-earnings ratio of 42.63, a price-to-earnings-growth ratio of 2.14 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company had revenue of $906.60 million during the quarter, compared to the consensus estimate of $927.56 million. During the same quarter last year, the company earned $0.84 earnings per share. Edwards Lifesciences’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences will post 4.7 earnings per share for the current year.

In related news, VP Huimin Wang sold 33,800 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $150.43, for a total transaction of $5,084,534.00. Following the completion of the sale, the vice president now owns 81,665 shares in the company, valued at approximately $12,284,865.95. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Schack Wesley W. Von sold 1,319 shares of Edwards Lifesciences stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $160.96, for a total value of $212,306.24. Following the sale, the director now owns 2,134 shares of the company’s stock, valued at approximately $343,488.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 212,192 shares of company stock valued at $31,055,823. 1.84% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of EW. FMR LLC grew its holdings in Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after buying an additional 1,663,511 shares during the period. Brown Advisory Inc. grew its holdings in Edwards Lifesciences by 2.2% in the 3rd quarter. Brown Advisory Inc. now owns 3,950,371 shares of the medical research company’s stock valued at $687,760,000 after buying an additional 84,355 shares during the period. Capital Research Global Investors grew its holdings in Edwards Lifesciences by 164.8% in the 3rd quarter. Capital Research Global Investors now owns 3,545,266 shares of the medical research company’s stock valued at $617,231,000 after buying an additional 2,206,539 shares during the period. Janus Henderson Group PLC grew its holdings in Edwards Lifesciences by 117.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,505,128 shares of the medical research company’s stock valued at $436,144,000 after buying an additional 1,350,879 shares during the period. Finally, Disciplined Growth Investors Inc. MN grew its holdings in Edwards Lifesciences by 1.8% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,063,704 shares of the medical research company’s stock valued at $359,291,000 after buying an additional 36,418 shares during the period. Hedge funds and other institutional investors own 81.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Bear Market

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit